Tuesday, November 19, 2024
- 11:00AM-12:30PM
-
Abstract Number: 2686
Dose Escalation Safety Study of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis:Clinical Results and Mechanistic Analysis of Skin and Peripheral Blood Mononuclear Cells
Abstracts: Systemic Sclerosis & Related Disorders – Clinical III- 11:00AM-12:30PM
-
Abstract Number: 2669
Dysferlin Autoantibodies Compromise Sarcolemmal Repair Capacity and Contribute to the Pathogenesis of Idiopathic Immune Myopathies
Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science II- 11:00AM-12:30PM
-
Abstract Number: 2678
History of Cutaneous Lupus Promotes Blood and Skin Interferon Signatures in SLE Patients
Abstracts: SLE – Diagnosis, Manifestations, & Outcomes III: Targets, Outcomes & Comorbidity- 11:00AM-12:30PM
-
Abstract Number: 2688
HLA-DRB4: A Novel Susceptibility Locus in Systemic Sclerosis Patients with Severe Calcinosis
Abstracts: Systemic Sclerosis & Related Disorders – Clinical III- 11:00AM-12:30PM
-
Abstract Number: 2662
In Vivo Generation of B Cell Depleting CAR T Cell Therapies for Treatment of Autoimmune Diseases
Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II- 11:00AM-12:30PM
-
Abstract Number: 2677
N-Acetylcysteine Blocks the Mechanistic Target of Rapamycin in Pro-Inflammatory Effector-Memory CD4 and CD8 T Cells Re-Expressing CD45RA in Patients with Active Systemic Lupus Erythematosus
Abstracts: SLE – Diagnosis, Manifestations, & Outcomes III: Targets, Outcomes & Comorbidity- 11:00AM-12:30PM
-
Abstract Number: 2683
Optical Coherence Angiography: A Non-invasive, Safe Method for Assessing the Systemic Sclerosis Related Vasculopathy Beyond Nailfold Capillaries
Abstracts: Systemic Sclerosis & Related Disorders – Clinical III- 11:00AM-12:30PM
-
Abstract Number: 2679
Predictors of Fracture in SLE: A Longitudinal Cohort Study
Abstracts: SLE – Diagnosis, Manifestations, & Outcomes III: Targets, Outcomes & Comorbidity- 11:00AM-12:30PM
-
Abstract Number: 2672
Prevention of the Development of Rheumatoid Arthritis by a 1-year Course of Methotrexate in ACPA-negative Arthralgia Patients at Increased Risk for Rheumatoid Arthritis: 4 Year Results of the TREAT EARLIER Trial
Abstracts: RA – Treatment II: Refining Use of Established Therapies- 11:00AM-12:30PM
-
Abstract Number: 2674
Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a 1st-Line Tumor Necrosis Factor Inhibitor in the United States
Abstracts: RA – Treatment II: Refining Use of Established Therapies- 11:00AM-12:30PM
-
Abstract Number: 2693
Risk Factors for Relapse in ANCA-Associated Vasculitis Among Patients with Relapse After Induction of Remission with Rituximab
Abstracts: Vasculitis – ANCA-Associated II- 11:00AM-12:30PM
-
Abstract Number: 2670
Sera from Patients with Idiopathic Inflammatory Myopathy Induces Muscle Weakness, Mitochondrial Dysfunction and Induction of Cytokines in Isolated Skeletal Muscle
Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science II- 11:00AM-12:30PM
-
Abstract Number: 2671
Subcutaneous Abatacept vs Adalimumab Head-to-Head Comparison in Adults with Early, Dual Seropositive Rheumatoid Arthritis, Positive for the Shared Epitope HLA Class II Risk Alleles, and an Inadequate Response to Methotrexate: Results from a Phase 3 Trial
Abstracts: RA – Treatment II: Refining Use of Established Therapies- 11:00AM-12:30PM
-
Abstract Number: 2682
The Forgotten Costs of SLE: Estimating Indirect Costs in a National SLE Cohort